Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Breast cancer survivors who developed incident myocardial infarction or heart failure exhibited increased risk for adverse oncologic outcomes, according to a population-based cohort study.The findings ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Spinraza treatment does not lead to significant kidney dysfunction in SMA patients with types 1 and 2, a safety and efficacy ...

New York City Blood Center Enterprises (“NYBCe”) today announced that their researchers have uncovered a critical mechanism that could potentially transform treatment approaches for Sickle Cell ...

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...